Welcome to our dedicated page for Fortrea Holdings SEC filings (Ticker: FTRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Fortrea Holdings Inc. filings document the public-company disclosures of a Nasdaq-listed contract research organization. The company’s 8-K reports furnish operating results and financial condition updates, including revenue, profitability measures, book-to-bill metrics, guidance and related press release exhibits.
Fortrea’s regulatory filings also cover proxy governance, annual meeting matters, board composition, executive compensation and inducement award plans. Capital-structure disclosures include common stock, rights to purchase Series A preferred stock, senior secured notes activity and other debt or equity matters tied to the company’s clinical development services business.
Fortrea Holdings Inc. Chief Financial Officer Jill G. Mcconnell exercised restricted stock units and sold shares to cover taxes. On March 9, 2026, 15,283 Restricted Stock Units were settled into 15,283 shares of common stock at a conversion price of $0.00 per share on their scheduled vesting date. On March 10, 2026, a total of 5,061 common shares were sold in open-market transactions at weighted average prices of $8.93 and $9.21 per share to satisfy tax withholding obligations under the company’s equity incentive plans, which the company describes as mandated “sell to cover” transactions and not discretionary trades. After these transactions, Mcconnell directly holds 69,796 shares of common stock and 156,131 RSUs, reflecting her ongoing equity stake in Fortrea.
Parks Robert reported acquisition or exercise transactions in this Form 4 filing.
Fortrea Holdings Inc. reported that Chief Accounting Officer Robert Parks received a grant of 22,893 Restricted Stock Units (RSUs) tied to Fortrea common stock. Each RSU represents one future share, and they vest in three substantially equal annual installments beginning on March 6, 2027. Following this compensation award, Parks holds an aggregate 90,614 RSUs, aligning his incentives with the company’s long-term performance rather than reflecting any open-market stock purchase or sale.
Morais Mark A. reported acquisition or exercise transactions in this Form 4 filing.
Fortrea Holdings Inc. reported that Chief Operating Officer Mark A. Morais received new equity awards in the form of restricted stock units and performance stock units tied to Fortrea common stock. He was granted 52,030 RSUs, each representing one share, vesting in three roughly equal annual installments starting on March 6, 2027. These RSUs bring his aggregate RSU holdings to 131,251 units.
Morais also received 66,667 performance stock units, each representing a contingent right to one share of common stock. These PSUs vest based on Fortrea’s share price reaching specified levels at the end of a three-year performance period and are shown with an expiration date of December 31, 2028, reflecting a long-term, performance-based component of his compensation.
Mcconnell Jill G. reported acquisition or exercise transactions in this Form 4 filing.
Fortrea Holdings Inc. reported new equity awards for its Chief Financial Officer, Jill G. Mcconnell. On March 6, 2026, she received 88,450 Restricted Stock Units, each representing one future share of common stock, bringing her total RSUs to 171,414.
The RSUs vest in three substantially equal annual installments beginning on March 6, 2027. She was also granted 66,667 Performance Stock Units, each tied to one share of common stock and vesting based on the stock reaching specified prices at the end of a three-year performance period.
FTRE reported a proposed sale of 4,599 shares of Common Stock via a Form 144 notifying the broker of an intended disposition tied to restricted stock vesting on 03/09/2026.
The filing also records a past disposition of 1,179 common shares on 02/10/2026 by Mark A. Morais.
Jill G. Mcconnell filed a Form 144 reporting a sale of 881 shares of Common Stock on 02/10/2026 and listing 5,061 restricted shares tied to a vesting event dated 03/09/2026 as securities to be sold in connection with compensation.
Fortrea Holdings Inc. is a global contract research organization providing phase I–IV clinical trial management, clinical pharmacology and consulting services to pharmaceutical, biotechnology and medical device companies. The company operates in about 100 countries with approximately 14,300 employees and one reporting segment, Clinical Services.
Fortrea, spun off from Labcorp, highlights strengths in oncology, where 40% of 2025 full-service therapeutic revenue came from oncology studies, and an estimated $41 billion addressable share of a forecast ~$145 billion 2026 clinical development market. It notes customer concentration, funding dependence, regulatory, data privacy, technology and cybersecurity risks as key challenges.
Fortrea Holdings reported fourth-quarter 2025 revenue of $660.5 million and full‑year revenue of $2,723.4 million, roughly flat versus 2024. Fourth‑quarter GAAP net loss narrowed to $32.5 million, while full‑year GAAP net loss widened sharply to $986.2 million.
The full‑year loss was driven largely by a non‑cash goodwill impairment charge of $797.9 million recorded in the first half of 2025. Excluding this and other adjustments, full‑year adjusted net income was $40.4 million and adjusted EBITDA was $189.9 million. Free cash flow for 2025 was $88.3 million, and year‑end cash stood at $174.6 million against gross debt of $1,066.3 million.
Operationally, Fortrea reported a fourth‑quarter book‑to‑bill ratio of 1.14x and a trailing 12‑month book‑to‑bill of 1.02x, with backlog of $7,728.0 million at December 31, 2025. For 2026, the company targets revenue of $2,550 million to $2,650 million and adjusted EBITDA of $190 million to $220 million.
Fortrea Holdings Inc. (FTRE) received an updated Schedule 13G/A from Sessa Capital entities and John Petry reporting a passive ownership position. The group reports beneficial ownership of 3,993,550 shares of Fortrea common stock, representing 4.32% of the outstanding class as of the reported date.
The reporting persons state they have no sole voting or dispositive power over these shares, but share voting and dispositive power over the full 3,993,550 shares. They certify the holdings are not intended to change or influence control of Fortrea.